---
title: "Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond"
description: "Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond"
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond

npj Biomed. Innov. | 2026 Feb

[![view publication](https://no-cache.hubspot.com/cta/default/14556940/0bcb63c8-9bf9-403a-8c3d-2ad4aadc7873.png)](https://cta-redirect.hubspot.com/cta/redirect/14556940/0bcb63c8-9bf9-403a-8c3d-2ad4aadc7873)

![](https://resources.huborganoids.nl/hubfs/publication-thumb-feb26.png)

## Abstract

Patient-derived-organoids (PDOs) are valuable tools for predicting individual responses to cancer treatments. However, current screening methods require large numbers of PDOs, resulting in long turnaround times and limiting clinical use. This study aimed to streamline the process by automating PDO seeding with the Yamaha Cell Handler™ (YCH). We optimized the YCH to pick and place up to ten PDOs per well, significantly reducing sample requirements compared to conventional methods. Assay optimization included evaluating seeding densities, devices, readouts, and measurement techniques. We validated the miniaturized assay by comparing it to standard screens and correlating organoid responses with patient outcomes. Our proof-of-concept demonstrated that mCRC PDOs respond to chemotherapy and targeted treatments in a way that closely matches results from traditional assays. This miniaturized automated platform enables efficient, high-quality drug screening with fewer cells, offering promising potential for faster, personalized cancer treatment predictions in clinical settings.

## Discover more from HUB:

Explore our organoid screening platform 

[discover more](https://www.huborganoids.nl/services/hub-drug-screening/)

Discover other publications on patient-derived organoids.

[browse now](https://www.huborganoids.nl/resources/)

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*